In recent years, we have employed multiple omics approaches, including microarray, ChIP-seq, phosphoproteomics, and secondary analyses of high-throughput data, to identify IRF4 transcriptional targets and elucidate its functions in hematological malignancies and other biological settings [61]. This evidence concerns the gene IRF4 and hematologic disorder.